Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRME for Esophageal Squamous Cell Neoplasia
NCT02029937Phase 2Unknown
- Start
- Jan 2014
- Primary completion
- Dec 2021
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial (2 arms). Primary endpoints: Diagnostic Yield at 1 day, Patients Saved from Biopsy at 1 day and 1 more. Status: unknown.
Beyond the preview
Go deeper on NCT02029937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029937.